Alpha-Methylacyl-CoA Racemase (AMACR) Antibody (FITC)
169€ (20 µg)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Name
Alpha-Methylacyl-CoA Racemase (AMACR) Antibody (FITC)
Category
Primary Antibodies
Provider
Abbexa
Reference
abx314048
Description
AMACR Antibody (FITC) is a Rabbit Polyclonal against AMACR conjugated to FITC.
Documentos del producto
Instrucciones
Data sheet
Especificaciones del producto
| Category | Primary Antibodies |
| Immunogen Target | Target: Alpha-Methylacyl-CoA Racemase (AMACR) Immunogen: Recombinant human Alpha-methylacyl-CoA racemase protein (13-175AA). |
| Host | Rabbit |
| Reactivity | Human |
| Detection Method | Laser Line: 488 Excitation/Emission: 499/515 |
| Recommended Dilution | Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | FITC |
| Isotype | IgG |
| Purity | > 95% |
| Purification | Purified by Protein G. |
| Size 1 | 20 µg |
| Size 2 | 50 µg |
| Size 3 | 100 µg |
| Size 4 | 200 µg |
| Size 5 | 1 mg |
| Form | Liquid |
| Buffer | 0.01 M PBS, pH 7.4, 0.03% Proclin-300 and 50% Glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid exposure to light. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | Q9UHK6 |
| Gene ID | 23600 |
| NCBI Accession | NP_001161067.1, NM_001167595.1, NP_055139.4, NM_014324.5 |
| OMIM | 214950 |
| Alias | AMACR |
| Background | Antibody anti-AMACR |
| Status | RUO |
| Note | THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION. |
Background
Alpha-Methylacyl-CoA Racemase (AMACR) is a mitochondrial and peroxisomal enzyme that catalyzes the racemization of alpha-methyl-branched fatty acid derivatives and bile acid intermediates, enabling their further metabolism via beta-oxidation. AMACR is critical in lipid metabolism, particularly in the breakdown of dietary branched-chain fatty acids and the processing of bile acids derived from cholesterol. It is highly expressed in tissues with active fatty acid metabolism, such as the liver and kidneys. Dysregulation or mutations in the AMACR gene are associated with metabolic disorders, including adult-onset sensory neuropathy and bile acid metabolism defects. Additionally, AMACR is a well-established biomarker for prostate cancer and other malignancies, as its overexpression is linked to cancer cell metabolism and tumor progression. Targeting AMACR enzymatic activity is being explored as a therapeutic strategy in cancer and metabolic disorders.